Clostridium massiliamazoniense sp. nov., New Bacterial Species Isolated from Stool Sample of a Volunteer Brazilian
Authors: Niokhor Dione
Didier Raoult
Pierre-Edouard Fournier
Cheikh Ibrahima Lo
Florence Fenollar
Journal: Current Microbiology (2020)
Discipline: MICROBIOLOGY
Keywords: gut microbiota; culturomics concept; anaerobic bacterium; Clostridium massiliamazoniense sp. nov.; fecal flora
Affiliations: Aix Marseille Univ, IRD, AP-HM, MEФI, Marseille, France., IHU-Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13385, Marseille Cedex 05, France., Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France., IHU-Méditerranée Infection, 19-21 Boulevard Jean Moulin, 13385, Marseille Cedex 05, France. ., Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France. .

Abstract:  The study of the gut microbiota by the "culturomics concept" permitted us to isolate, from human stool sample, an unknown anaerobic bacterium within the genus Clostridium for which we propose the name Clostridium massiliamazoniense sp. nov. It was isolated from the fecal flora of a healthy 49-year-old Brazilian male. Here, we describe the characteristics of this organism and its complete genome sequencing and annotation. Clostridium massiliamazoniense sp. nov., ND2T (= CSURP1360 = DSMZ 27309) is a Gram-positive, obligate anaerobic member of Firmicutes with a 3,732,600 bp-long genome and a G+C content of 27.6%. 

Retracted: No

PubPeer comments:
 The authors mention that: *A stool sample was collected from a 49-year-old volunteer and healthy male living in Brazil. The patient gave an informed and signed consent, and the agreement of the ethics committee of the Institut Fu00e9du00e9ratif de Recherche 48 (Aix-Marseille University, Marseille, France) was obtained under number 09-022.* The authors also mention that the sample has been obtained in 2013. In Brazil, research involving human beings is defined per [ResNo466](http: conselho.saude.gov.br resolucoes 2012 Reso466.pdf) as  research that, individually or collectively, have as a participant the human being, in its entirety or parts of it, and involve him in adirect or indirect, including the handling of your data, information or biological materials As per defined by [OrdNo2201](http: bvsms.saude.gov.br bvs saudelegis gm 2011 prt2201_14_09_2011.html), a biological material is defined as : * specimens, samples and aliquots of original material and its fractionated components *. And a specimen is defined as : * any human biological material such as organs, tissues, body fluids, obtained from a single subject, at a specific time *. Per [ResNo466](http: conselho.saude.gov.br resolucoes 2012 Reso466.pdf), research involving human beings must be submitted to the appreciation of the local CEP or to the CONEP when relevant. The study has prospectively recruited a healthy participant to collect a human biologic material (stool) for research purpose. However, the authors didn t mention any approval from a local brazilian ethics committe, a CEP or the Conep. The exportation of human biologic material from Brazil should also obtain an approval from Brazilian Health Authority (see [Manual of Transport of Human Biological Material](http: antigo.anvisa.gov.br resultado-de-busca?p_p_id=101 p_p_lifecycle=0 p_p_state=maximized p_p_mode=view p_p_col_id=column-1 p_p_col_count=1 _101_struts_action=%2Fasset_publisher%2Fview_content _101_assetEntryId=4048608 _101_type=document redirect=http%3A%2F%2Fantigo.anvisa.gov.br%2Fresultado-de-busca%3Fp_p_id%3D3%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_3_groupId%3D0%26_3_keywords%3DManual%2Bde%2BVigil%25C3%25A2ncia%2BSanit%25C3%25A1ria%2Bsobre%2Bo%2Btransporte%2Bde%2Bmaterial%2Bbiol%25C3%25B3gico%2Bhumano%2Bpara%2Bfins%2Bde%2Bdiagn%25C3%25B3stico%2Bcl%25C3%25ADnico%26_3_cur%3D1%26_3_struts_action%3D%252Fsearch%252Fsearch%26_3_format%3D%26_3_formDate%3D1441824476958) The authors only mention an approval from a french local ethics committee affiliated to the institution as some of the authors. It would be in a great interest if the authors can mention the name of the Brazilian ethics committee which approved this study, the approval number, the date of the ethics approval. In the case of the authors didn t obtain an approval from a ethics committee in Brazil, can the authors explain the rationale and the reason of this waiver considering the [ResNo466](http: conselho.saude.gov.br resolucoes 2012 Reso466.pdf) and the [OrdNo2201](http: bvsms.saude.gov.br bvs saudelegis gm 2011 prt2201_14_09_2011.html) ? ,